BackenVVeno Medical - Warrants (30/05/2023) Overview

enVVeno Medical - Warrants (30/05/2023) Current Assets

Track enVVeno Medical - Warrants (30/05/2023)'s current assets ($22M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$22.08M
37.98% YoYΔ $-13.52M vs prior year quarter

Peer trimmed avg / median

Loading

enVVeno Medical - Warrants (30/05/2023) Current Assets History

Loading

enVVeno Medical - Warrants (30/05/2023) vs. peers: Current Assets Comparison

Loading

enVVeno Medical - Warrants (30/05/2023) Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

enVVeno Medical - Warrants (30/05/2023) (NVNOW) FAQ

enVVeno Medical - Warrants (30/05/2023)'s current assets stands at $22M as of June 2026. That compares with $36M in the prior-year period — down 38.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

enVVeno Medical - Warrants (30/05/2023) reported $22M in current assets versus $36M a year earlier — a 38.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $36M in the prior-year period — down 38.0% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how enVVeno Medical - Warrants (30/05/2023)'s current assets evolved across reporting periods, while the comparison chart places NVNOW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. enVVeno Medical - Warrants (30/05/2023)'s reading of $22M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.